| Literature DB >> 22511854 |
Ben S Cooper1, Theodore Kypraios, Rahul Batra, Duncan Wyncoll, Olga Tosas, Jonathan D Edgeworth.
Abstract
An important determinant of a pathogen's success is the rate at which it is transmitted from infected to susceptible hosts. Although there are anecdotal reports that methicillin-resistant Staphylococcus aureus (MRSA) clones vary in their transmissibility in hospital settings, attempts to quantify such variation are lacking for common subtypes, as are methods for addressing this question using routinely-collected MRSA screening data in endemic settings. Here we present a method to quantify the time-varying transmissibility of different subtypes of common bacterial nosocomial pathogens using routine surveillance data. The method adapts approaches for estimating reproduction numbers based on the probabilistic reconstruction of epidemic trees, but uses relative hazards rather than serial intervals to assign probabilities to different sources for observed transmission events. The method is applied to data collected as part of a retrospective observational study of a concurrent MRSA outbreak in the United Kingdom with dominant endemic MRSA clones (ST22 and ST36) and an Asian ST239 MRSA strain (ST239-TW) in two linked adult intensive care units, and compared with an approach based on a fully parametric transmission model. The results provide support for the hypothesis that the clones responded differently to an infection control measure based on the use of topical antiseptics, which was more effective at reducing transmission of endemic clones. They also suggest that in one of the two ICUs patients colonized or infected with the ST239-TW MRSA clone had consistently higher risks of transmitting MRSA to patients free of MRSA. These findings represent some of the first quantitative evidence of enhanced transmissibility of a pandemic MRSA lineage, and highlight the potential value of tailoring hospital infection control measures to specific pathogen subtypes.Entities:
Mesh:
Year: 2012 PMID: 22511854 PMCID: PMC3325179 DOI: 10.1371/journal.pcbi.1002454
Source DB: PubMed Journal: PLoS Comput Biol ISSN: 1553-734X Impact factor: 4.475
Figure 1Incidence and prevalence of TW and non-TW MRSA strains on ICU 1 and ICU 2.
Red and black filled areas indicate the number of patients known to be colonized or infected with TW and non-TW MRSA on each ward at each time point (assuming MRSA is not cleared during the ward stay). Vertical broken lines indicate the timing of interventions A, B and C. Symbols above each graph indicate the number of MRSA acquisitions and importations each day under baseline assumptions (see protocol S1 and table S1 in supporting information for details of assumptions and corresponding numbers under alternative assumptions).
Figure 2Expected numbers of secondary cases per case.
Top panel shows histograms for expected numbers of secondary cases resulting from each case on the two ICUs (combined) in each of the four study phases (red is TW MRSA, white is non-TW) as calculated using method 1. The scatterplot (bottom panel) shows the same data, plotted according to the date MRSA was first isolated. Dates of interventions A, B and C are indicated by broken vertical lines. Smoothed trend lines (lowess smoothing where 10% of the points influence the smoothed value) are also shown.
Figure 3estimates for MRSA types TW and non-TW obtained using method 1. Estimates of net single admission reproduction numbers () for TW clones (red) and non-TW clones (black) are shown in terms of the point estimate (central white line), 80% CIs (dark shaded region) and 95% CI (light shaded region) for each four-week averaged reproduction number obtained by averaging individual patient reproduction numbers according to the ICU admission date. Interventions A, B and C are indicated by vertical arrows.
Estimated ward-level reproduction numbers (s.e.) for TW and non-TW MRSA clones using method 1.
| Phases | |||||
| 1 | 2 | 3 | 4 | ||
| ICU1 | TW MRSA | 0.14 (0.10) | 0.65 (0.17) | 0.14 (0.08) | 0.54 (0.22) |
| ICU1 | Non-TW MRSA | 0.36 (0.03) | 0.31 (0.08) | 0.41 (0.07) | 0.14 (0.03) |
| ICU2 | TW MRSA | 0.73 (0.19) | 0.41 (0.11) | 0.58 (0.22) | 0.58 (0.17) |
| ICU2 | Non-TW MRSA | 0.40 (0.04) | 0.21 (0.06) | 0.52 (0.15) | 0.17 (0.03) |
| Combined ICUs | TW MRSA | 0.71 (0.17) | 0.50 (0.09) | 0.56 (0.17) | 0.64 (0.15) |
| Combined ICUs | Non-TW MRSA | 0.38 (0.02) | 0.20 (0.03) | 0.47 (0.08) | 0.15 (0.02) |
Phase-specific estimates of ward-level reproduction numbers for TW MRSA and Non-TW MRSA derived using Method 1.
estimates for TW and non-TW combined.
| Phases | P-value | |||||
| 1 | 2 | 3 | 4 | All phases | ||
| ICU1 | 0.0032 (0.0025, 0.0040) | 0.0030 (0.0017, 0.0054) | 0.0032 (0.0022, 0.0046) | 0.0012 (0.0008, 0.0017) | 0.0024 (0.0020, 0.0028) |
|
| ICU2 | 0.0036 (0.0029, 0.0040) | 0.0033 (0.0020, 0.0056) | 0.0037 (0.0025, 0.0054) | 0.0016 (0.0012, 0.0022) | 0.0028 (0.0024, 0.0032) |
|
| Combined | 0.0034 (0.0029, 0.0040) | 0.0032 (0.0022, 0.0047) | 0.0034 (0.0026, 0.0044) | 0.0014 (0.0011, 0.0018) | 0.0026 (0.0023, 0.0029) |
|
| P-value | 0.17 | 0.43 | 0.82 | 0.54 | 0.23 | |
Phase-specific estimates for the daily probability of a susceptible patient acquiring MRSA from an MRSA positive patient in the same ward, for ICU 1 and ICU 2 (without distinguishing between TW and non-TW strains). In the Combined row, the estimates are constrained to be the same in both wards, and the All phases column constrains the estimates to be the same in the four phases.
P-values test the null hypothesis that transmission does not vary between study phase (likelihood ratio test, df = 3).
P-values test the null hypothesis that transmission in the current phase does not differ between wards (likelihood ratio test, df = 1).
Estimates of the daily transmission probability (q) from one exposed to one susceptible patient.
| Complete Bacterial Interference | |||||||
| Phases | P-value | ||||||
| 1 | 2 | 3 | 4 | All phases | |||
| ICU1 | TW MRSA | 0.0010 (0.0002,0.0069) | 0.0030(0.0011,0.0084) | 0.0001(0.0000,0.0398) | 0.0027(0.0011,0.0064) | 0.0020(0.0011,0.0037) |
|
| Non-TW MRSA | 0.0031(0.0025,0.0040) | 0.0011(0.0003,0.0036) | 0.0030(0.0020,0.0045) | 0.0009(0.0006,0.0014) | 0.0021(0.0017,0.0025) | ||
| ICU2 | TW MRSA | 0.0040(0.0022,0.0074) | 0.0037 (0.0019,0.0071) | 0.0041(0.0019,0.0091) | 0.0021 (0.0011,0.0037) | 0.0031(0.0022,0.0042) |
|
| Non-TW MRSA | 0.0033(0.0027,0.0042) | 0.0026(0.0011,0.0063) | 0.0030(0.0019,0.0048) | 0.0014 (0.0009,0.0020) | 0.0025(0.0021,0.0030) | ||
| Both | TW MRSA | 0.0031(0.0017,0.0056) | 0.0035(0.0021,0.0061) | 0.0025(0.0011,0.0056) | 0.0022 (0.0014,0.0036) | 0.0027(0.0021,0.0037) |
|
| Non-TW MRSA | 0.0032(0.0027,0.0038) | 0.0018(0.0009,0.0037) | 0.0030(0.0022,0.0041) | 0.0011 (0.0008,0.0015) | 0.0023(0.0020,0.0026) | ||
| P-value | 0.94 | 0.14 | 0.69 | 0.03 | 0.28 | ||
Estimates of the daily transmission probability (q) from one exposed to one susceptible patient.
P-values test the null hypothesis that transmission varies between study phases but not MRSA types against the alternative that it varies between study phases and MRSA types (likelihood ratio test, df = 4).
P-values test the null hypothesis that transmission in the study phase does not differ between TW and Non-TW MRSA using combined data from both wards (likelihood ratio test, df = 1).